YHB Investment Advisors Inc. raised its holdings in shares of Celgene Co. (NASDAQ:CELG) by 11.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 89,897 shares of the biopharmaceutical company’s stock after acquiring an additional 9,188 shares during the quarter. YHB Investment Advisors Inc.’s holdings in Celgene were worth $5,761,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also modified their holdings of CELG. Northstar Investment Advisors LLC purchased a new position in shares of Celgene during the 4th quarter valued at $506,000. First Hawaiian Bank grew its position in shares of Celgene by 20.2% during the 4th quarter. First Hawaiian Bank now owns 22,124 shares of the biopharmaceutical company’s stock valued at $1,418,000 after purchasing an additional 3,718 shares in the last quarter. State of Alaska Department of Revenue grew its position in shares of Celgene by 1.7% during the 4th quarter. State of Alaska Department of Revenue now owns 111,846 shares of the biopharmaceutical company’s stock valued at $7,166,000 after purchasing an additional 1,867 shares in the last quarter. Moody National Bank Trust Division grew its position in shares of Celgene by 0.6% during the 4th quarter. Moody National Bank Trust Division now owns 83,322 shares of the biopharmaceutical company’s stock valued at $5,340,000 after purchasing an additional 487 shares in the last quarter. Finally, Fulton Bank N.A. grew its position in shares of Celgene by 3.4% during the 4th quarter. Fulton Bank N.A. now owns 31,719 shares of the biopharmaceutical company’s stock valued at $2,033,000 after purchasing an additional 1,050 shares in the last quarter. 72.80% of the stock is currently owned by institutional investors and hedge funds.
Shares of CELG stock traded up $0.53 during trading hours on Friday, reaching $87.48. 748,719 shares of the stock were exchanged, compared to its average volume of 12,926,124. Celgene Co. has a 12-month low of $58.59 and a 12-month high of $107.29. The company has a current ratio of 2.13, a quick ratio of 1.99 and a debt-to-equity ratio of 4.06. The stock has a market cap of $61.19 billion, a PE ratio of 12.78, a P/E/G ratio of 0.46 and a beta of 1.44.
Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 EPS for the quarter, topping analysts’ consensus estimates of $2.02 by $0.27. Celgene had a net margin of 19.64% and a return on equity of 108.76%. The firm had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.83 billion. Sell-side analysts forecast that Celgene Co. will post 7.45 EPS for the current year.
CELG has been the subject of a number of recent analyst reports. BidaskClub lowered shares of Celgene from a “hold” rating to a “sell” rating in a research report on Wednesday, October 24th. Zacks Investment Research lowered shares of Celgene from a “buy” rating to a “hold” rating in a research report on Wednesday, September 26th. Mizuho set a $117.00 target price on shares of Celgene and gave the stock a “buy” rating in a research report on Tuesday, October 30th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Celgene in a research report on Thursday, October 25th. Finally, Robert W. Baird upgraded shares of Celgene from a “neutral” rating to an “outperform” rating and set a $92.00 target price for the company in a research report on Friday, January 4th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $110.17.
TRADEMARK VIOLATION WARNING: This news story was first posted by Macon Daily and is the property of of Macon Daily. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://macondaily.com/2019/01/11/yhb-investment-advisors-inc-has-5-76-million-holdings-in-celgene-co-celg.html.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Article: What are the benefits of a balanced fund?
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.